Emergent BioSolutions announces publication on brincidofovir in Mpox

Emergent BioSolutions (EBS) announced the publication of a comprehensive review article, “Brincidofovir in the Era of Mpox,” in the peer-reviewed journal Expert Review of Anti-infective Therapy. This publication includes an overview of brincidofovir, in vitro and in vivo data, including human case studies of the investigational use of brincidofovir, the current evaluation for treating mpox infections in adults and pediatrics in the Democratic Republic of Congo, and the potential for combination therapy with tecovirimat for immunocompromised patients with severe disease. Mpox, formerly known as monkeypox, continues to pose a significant public health challenge, with ongoing regional and global outbreaks particularly in Central and West Africa. On August 14, 2024, the World Health Organization declared the current mpox outbreak a global Public Health Emergency of International Concern. This marks the second mpox PHEIC declared by the WHO in the past two years, which followed the regional emergency declaration by the Africa Centres for Disease Control and Prevention on August 13, 2024. This month, the U.S. Centers for Disease Control and Prevention issued an updated report on the surge of mpox around the world. As part of the ongoing effort to identify safe and effective treatments for mpox, brincidofovir is currently being evaluated by the Africa CDC in partnership with PANTHER in the MpOx Study in Africa, a double-blind, placebo-controlled clinical trial for people diagnosed with mpox, which initiated in January 2025. The study has received initial funding from Horizon Europe and Africa CDC.